Literature DB >> 21257674

Life-threatening cardiac arrhythmia after a single dose of nebulized epinephrine in pediatric emergency department.

Fatihi Hassan Toaimah, Khalid Al-Ansari.   

Abstract

Cardiac adverse effects are not commonly reported complications of nebulized epinephrine therapy. We present a case of critical cardiac arrhythmia developed at the Pediatric Emergency Department in an otherwise healthy infant after receiving 3 mg of L-epinephrine (1:1000) nebulization over a 90 min period for a diagnosis of bronchiolitis. Unstable ventricular tachycardia was found after the nebulization therapy that required chemical cardioversion. Frequent premature ventricular contractions (PVCs) were found initially following the cardiac insult that was controlled with oral amiodarone, and disappeared during follow-up. Although epinephrine inhalation is generally safe, adverse life-threatening events could be unpredictable and may evolve even after a single dose of nebulized epinephrine.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21257674     DOI: 10.1093/tropej/fmq123

Source DB:  PubMed          Journal:  J Trop Pediatr        ISSN: 0142-6338            Impact factor:   1.165


  3 in total

1.  Evidence for Clinicians: Nebulized epinephrine for croup in children.

Authors:  Atsushi Kawaguchi; Ari Joffe
Journal:  Paediatr Child Health       Date:  2015 Jan-Feb       Impact factor: 2.253

2.  Nebulized 0.5, 2.5 and 5 ml L-epinephrine for post-extubation stridor in children: a prospective, randomized, double-blind clinical trial.

Authors:  Paulo Sérgio Lucas da Silva; Marcelo Cunio Machado Fonseca; Simone Brasil Oliveira Iglesias; Emílio Lopes Junior; Vânia Euzébio de Aguiar; Werther Brunow de Carvalho
Journal:  Intensive Care Med       Date:  2011-11-26       Impact factor: 17.440

Review 3.  Recent evidence on the management of bronchiolitis.

Authors:  Alan R Schroeder; Jonathan M Mansbach
Journal:  Curr Opin Pediatr       Date:  2014-06       Impact factor: 2.856

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.